» Articles » PMID: 28229968

Cytotoxic and Toxicogenomic Effects of Silibinin in Bladder Cancer Cells with Different TP53 Status

Overview
Journal J Biosci
Specialties Biochemistry
Biology
Date 2017 Feb 24
PMID 28229968
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Silibinin is a natural phenol found in the seeds of the milk thistle plant. Recent data have shown its effectiveness for preventing/treating bladder tumours. Therefore, in this study we investigated the cytotoxic and toxicogenetic activity of silibinin in bladder cancer cells with different TP53 statuses. Two bladder urothelial carcinoma cell lines were used: RT4 (wild-type TP53 gene) and T24 (mutated TP53 gene). Cell proliferation, clonogenic survival, apoptosis rates, genotoxicity and relative expression profile of FRAP/mTOR, FGFR3, AKT2 and DNMT1 genes and of miR100 and miR203 were evaluated. Silibinin promoted decreased proliferation and increased late apoptosis in TP53 mutated cells. Increased early apoptosis rates, primary DNA damage, and decrease of cell colonies in the clonogenic survival assay were detected in both RT4 and T24 cell lines. Down-regulation of FRAP/mTOR, AKT2, FGFR3, DNMT1 and miR100 expression occurred in RT4 cells. Modulation of miR203 was observed in both cell lines. In conclusion, despite the reduction of clone formation in both cell lines, the toxicogenomic effect of silibinin on FRAP/mTOR, AKT2, FGFR3, DNMT1 and miR100 was dependent on the TP53 status. Taken together, the data confirmed the role of silibinin as an antiproliferative compound, whose mechanism of action was related to the TP53 status.

Citing Articles

A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment.

Ray P, Islam M, Islam M, Han A, Geng P, Aziz M Front Pharmacol. 2024; 15:1349745.

PMID: 38487172 PMC: 10937417. DOI: 10.3389/fphar.2024.1349745.


Global Trends in Research of Treatment on Bladder Cancer with Chinese Medicine Monomer from 2000 to 2021: A Bibliometric Analysis.

Li D, Zuo M, Hu X J Oncol. 2022; 2022:3382360.

PMID: 36245973 PMC: 9553534. DOI: 10.1155/2022/3382360.


Properties of flavonoids in the treatment of bladder cancer (Review).

Lv Y, Liu Z, Jia H, Xiu Y, Liu Z, Deng L Exp Ther Med. 2022; 24(5):676.

PMID: 36185766 PMC: 9522619. DOI: 10.3892/etm.2022.11612.


The Role of Epigenetic Modifications in Human Cancers and the Use of Natural Compounds as Epidrugs: Mechanistic Pathways and Pharmacodynamic Actions.

Bouyahya A, Mechchate H, Oumeslakht L, Zeouk I, Aboulaghras S, Balahbib A Biomolecules. 2022; 12(3).

PMID: 35327559 PMC: 8945214. DOI: 10.3390/biom12030367.


Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.

Koltai T, Fliegel L J Evid Based Integr Med. 2022; 27:2515690X211068826.

PMID: 35018864 PMC: 8814827. DOI: 10.1177/2515690X211068826.


References
1.
Aravindaram K, Yang N . Anti-inflammatory plant natural products for cancer therapy. Planta Med. 2010; 76(11):1103-17. DOI: 10.1055/s-0030-1249859. View

2.
Dobbin Z, Landen C . The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci. 2013; 14(4):8213-27. PMC: 3645739. DOI: 10.3390/ijms14048213. View

3.
Kaur M, Velmurugan B, Tyagi A, Deep G, Katiyar S, Agarwal C . Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft. Mol Cancer Ther. 2009; 8(8):2366-74. PMC: 2728169. DOI: 10.1158/1535-7163.MCT-09-0304. View

4.
Meireles Da Costa N, Hautefeuille A, Cros M, Melendez M, Waters T, Swann P . Transcriptional regulation of thymine DNA glycosylase (TDG) by the tumor suppressor protein p53. Cell Cycle. 2012; 11(24):4570-8. PMC: 3562302. DOI: 10.4161/cc.22843. View

5.
Luo J, Manning B, Cantley L . Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003; 4(4):257-62. DOI: 10.1016/s1535-6108(03)00248-4. View